FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, in case of an inadvertent administration of Ytracis, the radiotoxicity for the patient must be reduced by immediate (i.e. within 1 hour) administration of preparations containing chelators like Ca-DTPA or Ca- EDTA in order to increase the elimination of the radionuclide from the body.
Croatian: Zato, u slučaju nehotične primjene YTRACISa, mora se radiotoksičnost za pacijenta odmah sniziti (tj. unutar 1 sata) primjenom preparata koji sadrže kelate, poput Ca-DTPA ili Ca-EDTA, kako bi se pospješilo uklanjanje radionuklida iz tijela.
English: One vial contains 0.925 to 3.700 GBq (see section 6.5).
Croatian: Jedna bočica sadrži 0,925 do 3,700 GBq (vidjeti dio 6.5).
English: Kidneys Liver Bladder Ovaries Uterus Spleen 0.85 Bone Heart Lungs Intestines Muscles Testes
Croatian: Jajnici Maternica --Slezena Kost Srce Pluća Crijeva Mišići Testisi
English: A.LABELLING
Croatian: OZNAČAVANJE
English: The content of the vial of YTRACIS is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
Croatian: Sadržaj bočice YTRACISa ne smije se primijeniti u pacijenta izravno, već se mora koristiti za radioobilježavanje molekula nosača, kao što su monoklonska antitijela, peptidi ili druge tvari.
English: YTRACIS is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3 Contraindications).
Croatian: YTRACIS je kontraindiciran kod potvrñene trudnoće ili sumnje na trudnoću ili kada trudnoća nije isključena (vidjeti dio 4.3 Kontraindikacije).
English: The product should be aseptically withdrawn through the stopper using sterilised single use needle and syringe after disinfection of the stopper.
Croatian: Sadržaj treba aseptički izvući kroz čep pomoću sterilne jednokratne igle i štrcaljke nakon što se čep dezinficira.
English: Do not use YTRACIS: - if you are hypersensitive (allergic) to Yttrium (90Y) chloride or any of the other ingredients of
Croatian: Nemojte primati YTRACIS: - ako ste alergični (preosjetljivi) na itrijev (90Y) klorid ili bilo koji drugi sastojak ovog lijeka.
English: INFORMATION IN BRAILLE <Justification for not including Braille accepted>
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Prihvaćeno obrazloženje za nenavoñenje Brailleovog pisma.
English: Pregnancy: Ask your doctor or pharmacist for advice before taking any medicine.
Croatian: Dojenje: Upitajte svog liječnika ili ljekarnika prije nego uzmete bilo koji lijek.
English: Organ doses (mGy/MBq injected) and effective dose (Sv/GBq injected).
Croatian: Doze po organima (injicirano mGy/MBq) i efektivna doza (injicirano mSv/GBq).
English: The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations.
Croatian: Doza zračenja nakon terapijskog izlaganja radiofarmaceuticima može rezultirati većom incidencijom karcinoma i mutacija.
English: Alternative techniques which do not involve ionising radiation should always be considered.
Croatian: Uvijek je potrebno razmotriti alternativne dijagnostičke tehnike koje ne uključuju ionizirajuće zračenje.
English: Do not administer YTRACIS directly to the patient.
Croatian: YTRACIS ne primjenjujte izravno u bolesnika.
English: Batch N°: {XXXXX}
Croatian: Vol.: {Z} ml
English: The vial is supplied in a lead pot of appropriate thickness.
Croatian: Bočica se isporučuje u olovnoj posudi odgovarajuće debljine.
English: 1 vial contains 0.5 to 2 ml (corresponding to 0.925 to 3.700 GBq calibrated three or four days after the manufacturing date) depending on the ordered radioactivity.
Croatian: 1 bočica sadrži 0,5 do 2 ml (što odgovara 0,925 do 3,700 GBq kalibrirano tri ili četiri dana od datuma izrade) ovisno o naručenoj radioaktivnosti.
English: No studies on the effects on the ability to drive and use machines have been performed.
Croatian: Nisu provedena ispitivanja o utjecaju ovog lijeka na sposobnost upravljanja vozilima i rada na strojevima.
English: Hydrochloric acid 30%, water for injections.
Croatian: 30% kloridna kiselina, voda za injekcije.
English: Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Croatian: Izlaganje ionizirajućem zračenju povezano je s nastankom karcinoma, a može uzrokovati i nastanak nasljednih poremećaja.
English: Clear, colourless solution, free of particulate matter.
Croatian: Bistra, bezbojna otopina, bez vidljivih čestica.
English: Absorbed dose per unit activity administered (mGy/MBq)
Croatian: Apsorbirana doza po jedinici primijenjene radioaktivnosti (mGy/MBq)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of sterile solution contains 1.850 GBq Yttrium (90Y) chloride, at the date of calibration, corresponding to 92 ng of Yttrium.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV 1 ml sterilne otopine sadrži 1,850 GBq itrijevog (90Y) klorida, na datum kalibracije, što odgovara 92 ng itrija.
English: However, a post-exposure interval >1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Croatian: Ako je interval nakon ekspozicije duži od 1 sata, to ne isključuje primjenu niti učinkovitost kelata, iako je njihov učinak tada slabiji.
English: This medicine is a clear and colourless solution which is packed in a colourless Type I glass 2-ml vial closed with Teflon-coated bromobutyl rubber stopper and aluminium overseal.
Croatian: Lijek je bistra i bezbojna otopina pakirana u bočici od bezbojnog stakla tipa I, od 2 ml, koja je zatvorena teflonom obloženim čepom od brombutilne gume i aluminijskim zaštitnim zatvaračem.
English: B CONDITIONS OF THE MARKETING AUTHORISATION
Croatian: B UVJETI ODOBRENJA
English: Hospital personnel will ensure that the product is stored correctly and not administered to you after the stated expiry date.
Croatian: Bolničko će se osoblje pobrinuti da se lijek čuva na ispravan način i da Vam se primijeni unutar navedenog roka valjanosti.
English: YTRACIS is not to be administered directly to the patient.
Croatian: YTRACIS se ne smije primijeniti izravno u pacijenta.
English: Radionuclide procedures carried out in pregnant women also involve radiation doses to the foetus.
Croatian: Radionuklidni postupci provedeni u trudnica takoñer dovode i do ozračivanja ploda.
English: Radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates, with Yttrium (90Y) chloride is very sensitive to the presence of trace metal impurities.
Croatian: Radioaktivno označavanje molekula nosača itrijevim (90Y) kloridom, kao što su monoklonska antitijela, peptidi i drugi spojevi, vrlo je osjetljivo na prisutnost tragova metalnih nečistoća.
English: The following preparations must be available in medical institutions, which use Ytracis for radiolabelling of carrier molecules for therapeutic purposes: Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Croatian: U ustanovama koje koriste YTRACIS za radioobilježavanje molekula nosača koji se koriste u terapijske svrhe, moraju biti dostupni sljedeći preparati: Ca-DTPA (Kalcijev trinatrij-dietilen-triamin-pentaacetat) ili Ca-EDTA (Kalcijev dinatrij-etilendiamin-tetraacetat)
English: A vial contains 0.5 ml (0.925 GBq at calibration) to 2 ml (3.700 GBq at calibration).
Croatian: Bočica sadrži 0,5 ml (0,925 GBq u vrijeme kalibracije) do 2 ml (3,700 GBq u vrijeme kalibracije).
English: In the rat, following intravenous administration, Yttrium (90Y) chloride is rapidly cleared from the blood.
Croatian: Kod štakora, nakon intravenske primjene, itrijev (90Y) klorid se brzo uklanja iz plazme.
English: The presence of free Yttrium (90Y) chloride in the body after an inadvertent administration of Ytracis will lead to increase bone marrow toxicity and haematopoetic stem cell damage.
Croatian: Prisutnost slobodnog itrijevog (90Y) klorida u tijelu nakon nehotične primjene YTRACISa, dovest će do povećane toksičnosti za koštanu srž i oštećenja hematopoetskih matičnih stanica.
English: For in vitro radiolabelling.
Croatian: Za in vitro radioaktivno označavanje.
English: Each millilitre of solution contains 1.850 GBq of Yttrium (90Y) chloride at the date of calibration.
Croatian: Svaki mililitar otopine sadrži 1,850 GBq itrijevog (90Y) klorida na dan kalibracije.
English: Because there are strict laws covering the use, handling and disposal of radioactivity, YTRACIS will always be used in a hospital or a similar setting.
Croatian: Strogi zakonski propisi ograničavaju primjenu, rukovanje i odlaganje radioaktivnih tvari, stoga se YTRACIS primjenjuje samo u bolničkim ili bolnicama sličnim uvjetima.
English: BEFORE YOU USE YTRACIS
Croatian: 2. PRIJE NEGO POČNETE PRIMATI YTRACIS
English: These chelating agents suppress yttrium radiotoxicity by an exchange between the calcium ion and the yttrium due to their capacity of forming water soluble complexes with the chelating ligands (DTPA, EDTA).
Croatian: Ovi kelirajući agensi suprimiraju radiotoksičnost itrija zamjenom izmeñu iona kalcija i itrija, formirajući tako u vodi topive komplekse s kelirajućim ligandima (DTPA, EDTA).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS GLASS VIAL
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKOVANJE STAKLENA BOČICA
English: Cal : {DD/MM/YYYY} (12 h CET)
Croatian: : {DD/MM/GGGG} (12h SEV)
English: YTRACIS is intended for radiolabelling of medicinal products to treat specific diseases, which are subsequently administered by approved route.
Croatian: YTRACIS je namijenjen za radioobilježavanje lijekova za liječenje odreñenih bolesti, koji se potom primjenjuju dozvoljenim putem primjene.
English: 5 How to store YTRACIS Further information
Croatian: Kako čuvati YTRACIS Dodatne informacije
English: YTRACIS is a radiopharmaceutical precursor.
Croatian: YTRACIS je radiofarmaceutski prekursor.
English: In the liver, 18 % of the injected activity is taken up 5 min after injection.
Croatian: 5 minuta nakon aplikacije u jetri se nakupi 18% injicirane radioaktivnosti.
English: Name and address of the manufacturer responsible for batch release
Croatian: Naziv i adresa proizvoñača odgovornog za puštanje serije lijeka u promet
English: The toxicity of the free Yttrium (90Y) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Croatian: Toksičnost slobodnog itrija (90Y) zbog njegovog in vivo oslobañanja od radioobilježene biomolekule tijekom terapije može se smanjiti naknadnom primjenom kelirajućih agenasa.
English: Since YTRACIS is administered by a doctor under strictly controlled conditions there is little chance of possible overdose.
Croatian: Ako primite više YTRACISa nego li biste to trebali Kako YTRACIS primjenjuje liječnik u strogo kontroliranim uvjetima, predoziranje je malo vjerojatno.
English: Store in accordance with local regulations for radioactive substances.
Croatian: Čuvati sukladno lokalnim propisima o radioaktivnim tvarima.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION YTRACIS Yttrium (90Y) chloride
Croatian: NAZIV GOTOVOG LIJEKA I PUT PRIMJENE LIJEKA YTRACIS itrijev (90Y) klorid
English: YTRACIS is a radioactive medicine used in combination with another medicine product which targets specific body cells.
Croatian: YTRACIS je radioaktivni lijek koji se koristi u kombinaciji s drugim lijekom koji ciljano djeluje na odreñene stanice u tijelu.
English: The quantity of YTRACIS required for radiolabelling and the quantity of Yttrium (90Y)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Croatian: Količina Ytracisa potrebna za radioobilježavanje i količina s itrijem (90Y) obilježenog lijeka koja će se potom primijeniti, ovisi o tom radioobilježenom lijeku i njegovoj namjeni.
English: Colourless Type I glass 2-ml vial, closed with Teflon-coated bromobutyl rubber stopper and aluminium overseal.
Croatian: I od 2 ml, zatvorena teflonom obloženim čepom od brombutilne gume i aluminijskim zaštitnim zatvaračem.
English: The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Yttrium (90Y) to the radiation dose following the administration of Yttrium (90Y)-labelled medicinal product or resulting from an accidental intravenous injection of YTRACIS.
Croatian: Dozimetrijska tablica u nastavku omogućuje procjenu doprinosa nekonjugiranog itrija (90Y) dozi zračenja nakon aplikacije itrijem (90Y) označenog lijeka ili nakon nehotične intravenske injekcije
English: YTRACIS is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by approved route.
Croatian: YTRACIS je namijenjen za in vitro radioobilježavanje lijekova, koji se potom primjenjuju dozvoljenim putem primjene.
English: EXP {DD/MM/YYYY} (12h CET)
Croatian: Rok valjanosti {DD/MM/GGGG} (12h SEV)
English: When it is necessary to administer radioactive medicinal products to women of childbearing potential, information should always be sought about pregnancy.
Croatian: Kad je potrebno primijeniti radioaktivne lijekove kod žena fertilne dobi, treba provjeriti je li pacijentica trudna.
English: Marketing Authorisation Holder and Manufacturer
Croatian: Nositelj odobrenja za stavljanje gotovog lijeka u promet i proizvoñač
English: See section 12, for detailed instructions of product preparation.
Croatian: Za detaljne upute o pripremi lijeka vidjeti dio 12.
English: NAME OF THE MEDICINAL PRODUCT YTRACIS radiopharmaceutical precursor, solution.
Croatian: NAZIV GOTOVOG LIJEKA YTRACIS radiofarmaceutski prekursor, otopina.
English: Y) chloride with other medicinal products are known because no studies have investigated this issue.
Croatian: Primjena drugih lijekova: Nisu poznate interakcije itrijevog (90Y) klorida s drugim lijekovima, jer takva ispitivanja nisu provedena.
English: For further information regarding the treatment and possible effects caused by the medicinal product to be radiolabelled please refer to the package leaflet of the medicinal product to be radiolabelled.
Croatian: Za dodatne podatke o primjeni i mogućim nuspojavama lijeka koji se radioobilježava molimo pogledajte upute za taj lijek.
English: PHARMACEUTICAL FORM Radiopharmaceutical precursor, solution.
Croatian: OBLIK Radiofarmaceutski prekursor, otopina.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of the first authorisation: 24/03/2003
Croatian: Datum prvog odobrenja: 24.03.2003.
English: Act.: {Y} GBq/ml
Croatian: : {DD/MM/GGGG} (12 h SEV) Akt.: {Y} GBq/ml
English: Appropriate aseptic precautions should be taken, complying with the requirements of Good Pharmaceutical Manufacturing Practice, in order to maintain the sterility of YTRACIS and to maintain sterility throughout the labelling procedures.
Croatian: Kako bi se sačuvala sterilnost YTRACIS-a i održala tijekom postupka obilježavanja, potrebno je poduzeti odgovarajuće aseptičke mjere u skladu sa zahtjevima Dobre farmaceutske proizvoñačke prakse u pripremi lijekova.
English: Liver uptake decreases then to 8.4 % 24 hours after injection.
Croatian: 24 sata nakon aplikacije akumulacija u jetri pada na 8,4%.
English: Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation will be available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Podaci o dozimetriji zračenja za svaki lijek nakon primjene tog radioobilježenog lijeka bit će dostupni u Sažetku opisa svojstava lijeka/uputa o lijeku koji se radioobilježava.
English: Only syringe needles (for example non-metallic) with proven resistance to dilute acid should be used to minimise trace metal impurity levels.
Croatian: Kako bi se osigurala minimalna razina tragova metalnih nečistoća, smiju se koristiti samo injekcijske igle (na primjer nemetalne) koje su dokazano otporne na djelovanje razrijeñene kiseline.
English: - The active substance is Yttrium (90Y) chloride.
Croatian: - Djelatna tvar je itrijev (90Y) klorid.
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE Any unused product or waste material should be disposed of in accordance with local requirements.
Croatian: POSEBNE MJERE ZA ZBRINJAVANJE NEISKORIŠTENOG LIJEKA ILI OTPADNIH MATERIJALA KOJI POTJEČU
English: Possible side effects following the intravenous administration of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with YTRACIS, will be dependent on the specific medicinal product being used.
Croatian: Moguće nuspojave nakon intravenske primjene itrijem (90Y) obilježenog lijeka pripremljenog radioobilježavanjem pomoću YTRACISa, ovisit će o specifičnom lijeku koji se koristi.
English: Hydrochloric acid 30 %
Croatian: 30 % kloridna kiselina voda za injekcije
English: For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Za više podataka, pogledajte uputu o lijeku koji treba radioobilježiti.
English: Such information will be supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Podaci o tome bit će navedeni u Sažetku opisa svojstava lijeka/uputa o lijeku koji se radioobilježava.
English: The product label includes the appropriate storage conditions and the expiry date for the batch of product.
Croatian: Na pakovanju lijeka su navedeni uvjeti ispravnog čuvanja i istek roka valjanosti za dotičnu seriju lijeka.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Croatian: 11. IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET
English: Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr).
Croatian: Farmakoterapijska skupina: Nije primjenjivo, ATK oznaka: Nije primjenjivo Itrijev (90Y) klorid nastaje raspadanjem njegovog radioaktivnog prekursora stroncija (90Sr).
English: The two main organs where Yttrium (90Y) chloride distributes are the liver and bones.
Croatian: Jetra i kosti su dva glavna organa u koje se distribuira itrijev (90Y) klorid.
English: For information on contraindications to particular Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with YTRACIS, refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Za kontraindikacije pojedinog, itrijem (90Y) obilježenog lijeka, koji je pripremljen radioobilježavanjem pomoću YTRACISa, pogledati u Sažetku opisa svojstava lijeka/uputa o lijeku onog lijeka koji se radioobilježava.
English: For information concerning special warnings and precautions for use of Yttrium (90Y)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Podatke o posebnim upozorenjima i mjerama opreza pri primjeni itrijem (90Y) obilježenih lijekova potražite u Sažetku opisa svojstava lijeka/uputa o lijeku koji treba radioobilježiti.
English: The absorbed dose to the uterus following administration of Yttrium (90Y)-labelled medicinal products is dependent on the specific medicinal product being radiolabelled and is to be specified in the Summary of Product Characteristics/ package leaflet of the medicinal product to be radiolabelled.
Croatian: Nakon primjene itrijem (90Y) obilježenog lijeka apsorbirana doza u uterusu ovisi o specifičnom radioobilježenom lijeku i podatke o tome treba potražiti u Sažetku opisa svojstava lijeka/uputa o lijeku koji treba radioobilježiti.
English: What YTRACIS is and what it is used for Before you use YTRACIS How to use YTRACIS Possible side effects
Croatian: Što je YTRACIS i za što se koristi Prije nego počnete primati YTRACIS
English: A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Croatian: A PROIZVOðAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: For information concerning interactions associated with the use of Yttrium (90Y)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Podatke o interakcijama povezanim s primjenom itrijem (90Y) obilježenih lijekova potražite u Sažetku opisa svojstava lijeka/uputa o lijeku koji treba radioobilježiti.
English: 4.8 Undesirable Effects
Croatian: 4.8 Nuspojave
English: GENERAL CLASSIFICATION FOR SUPPLY Medical product subject to medical prescription.
Croatian: 13. BROJ SERIJE Broj serije: {XXXXX} 14. NAČIN PROPISIVANJA LIJEKA Lijek se izdaje na recept.
English: The pharmacodynamic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with YTRACIS, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakodinamička svojstva itrijem (90Y) obilježenih lijekova pripremljenih radioobilježavanjem pomoću YTRACISa prije same primjene, ovisit će o svojstvima lijeka koji se radioobilježava.
English: The pharmacokinetic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with YTRACIS, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakokinetička svojstva itrijem (90Y) obilježenih lijekova pripremljenih radiobilježavanjem pomoću YTRACISa prije same primjene, ovisit će o svojstvima lijeka koji se radioobilježava.
English: Take special care with YTRACIS: YTRACIS is not to be administered directly to the patient.
Croatian: Budite posebno oprezni s YTRACISom:
English: F-91192 Gif-sur-Yvette Cedex FRANCE
Croatian: F-91192 Gif-sur-Yvette Cedex FRANCUSKA
English: Yttrium (90Y) chloride
Croatian: YTRACIS radiofarmaceutski prekursor, otopina. itrijev (90Y) klorid
English: Yttrium (90Y) chloride.
Croatian: YTRACIS radiofarmaceutski prekursor, otopina. itrijev (90Y) klorid.
English: labelled medicinal product will be dependent on the specific pharmaceutical being radiolabelled.
Croatian: obilježenog lijeka bit će navedena u Sažetku opisa svojstava lijeka/uputa o lijeku koji treba radioobilježiti.
English: The radiation dose received by the various organs following administration of a Yttrium (90Y)
Croatian: Utjecaj na sposobnost upravljanja vozilima i rada na strojevima nakon primjene itrijem (90Y)
English: Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Pogledajte Sažetak opisa svojstava lijeka/uputa o lijeku za lijek koji treba radioobilježiti.
English: Effective dose (Sv/1 GBq administered) Adult male Adult female 15 years 10 years 5 years
Croatian: Odrasli muškarac Odrasla žena 15 godina 10 godina 5 godina 1 godina Novoroñenče
English: The patient should avoid eating or drinking for 10 minutes after taking the medicine.
Croatian: Bolesnici trebaju izbjegavati unos hrane ili pića 10 minuta nakon uzimanja lijeka.
English: Sycrest asenapine
Croatian: Sycrest asenapin
English: This summary was last updated in 10-2015.
Croatian: Ovaj sažetak je posljednji put ažuriran u 10.2015.
English: It is available as sublingual tablets (5 and 10 mg).
Croatian: Dostupan je u sublingvalnim tabletama (5 i 10 mg).
English: It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Croatian: Poznat je pod nazivom „atipičan” antipsihotik jer se razlikuje od starijih antipsihotika koji su dostupni od 1950-ih godina.
English: Sycrest tablets should not be chewed or swallowed.
Croatian: Tablete lijeka Sycrest ne smiju se žvakati ili gutati.
English: This dose can be increased to 10 mg twice a day depending on how the patient responds.
Croatian: Ta se doza može povećati na 10 mg dvaput na dan ovisno o odgovoru bolesnika na terapiju.
English: Other information about Sycrest:
Croatian: Ostale informacije o lijeku Sycrest:
English: Sublingual tablets are tablets that are placed under the tongue, where they dissolve.
Croatian: Sublingvalne tablete su tablete koje se stavljaju pod jezik, gdje se otapaju.